What is the half-life (T1/2) of albumin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Half-Life of Albumin

The half-life of albumin is approximately 20 days in healthy individuals 1, 2.

Physiological Context

The turnover of human serum albumin is considerably shorter than hemoglobin, with a half-life ranging from 14-20 days 1. This relatively rapid turnover compared to hemoglobin (which has an erythrocyte lifespan of 120 days) makes albumin-based glycation markers more sensitive to short-term changes in glycemic control 1.

Key Physiological Details

  • Daily synthesis: Approximately 12 grams of albumin are synthesized daily by hepatic polyribosomes, representing about 10% of the intravascular albumin mass 2

  • Distribution: Only 40% of total body albumin resides in the intravascular compartment, with the remainder in extravascular spaces 2

  • Degradation: Albumin is degraded at a constant fractional catabolic rate, with approximately 30% catabolized by the liver, kidneys, and gastrointestinal tract 2

Clinical Variations in Half-Life

Critically Ill Patients

In critically ill surgical patients, the apparent plasma half-life is dramatically shortened to approximately 11.8 days (95% CI: 10.8-12.9) 3. This represents a nearly 50% reduction compared to healthy individuals and reflects the accelerated protein catabolism characteristic of critical illness 3.

Structural Integrity Requirements

The C-terminal end of albumin is essential for maintaining its long half-life 4. When the last C-terminal leucine residue (L585) is enzymatically cleaved, the half-life plummets to only 3.5 days 4, 5. This dramatic reduction occurs because:

  • Removal of L585 causes structural stabilization in regions of the principal FcRn (neonatal Fc receptor) binding domain 4
  • This structural change reduces FcRn binding affinity 4
  • FcRn-mediated recycling is the primary mechanism protecting albumin from intracellular degradation 6, 5

Pathological Conditions

The fractional catabolic rate can be modulated in chronic disease states 2:

  • Reduced in: protein deficiency, blind loop syndrome, cirrhosis, nephrotic syndrome, and gastrointestinal diseases 2
  • Increased with: albumin infusion (though this occurs slowly) 2

Clinical Implications

For Glycemic Monitoring

Because albumin has a shorter half-life than hemoglobin, glycated albumin (GA) reflects glycemic control over approximately 2-3 weeks (specifically the preceding 1-2 weeks for a single measurement) 1. This makes GA particularly useful when:

  • HbA1c cannot be reliably measured (e.g., hemolytic anemias, end-stage renal disease on hemodialysis) 1
  • Short-term glycemic changes need assessment after treatment adjustments 1

Important Caveats

Conditions affecting albumin turnover will alter GA levels independent of glucose control 1:

  • Accelerated turnover (hyperthyroidism, obesity, nephrotic syndrome): falsely lowers GA 1
  • Decreased turnover (hypothyroidism, liver cirrhosis): falsely elevates GA 1

For Nutritional Assessment

Prealbumin has an even shorter half-life of 2-3 days versus albumin's 20 days 1, making it theoretically more sensitive to acute nutritional changes, though this advantage is limited by similar confounding factors affecting both proteins 1.

Serum transferrin has an intermediate half-life of 8 days 1, but its utility is compromised by iron status effects, making it less clinically useful than albumin in dialysis populations 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.